drugset / Trial / NCT05688241
EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In this multi-center open-label, non-randomized phase I/II intervention study three consecutive doses of donor-derived EBV Tscm-CTLs will be administered to 10 patients with treatment-refractory EBV lymphoma, diseases or PTLDs. EBV Tscm-CTLs will derive from hematopoietic cell transplant (HCT) or third-party donors.
Timeline
- Start
- 2026-11
- Primary completion
- 2031-12
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donor-derived ex-vivo expanded EBV Tscm CTL | Cell therapy | 2e+06 cells/kg | Other |